How grade affects kidney cancer prognosis — what low and high grade mean over time

On average, yes, but average is the important word. Across large groups of patients, tumours with a higher WHO/ISUP grade come back more often and behave less predictably than low grade tumours of the same stage. That is why grade appears in almost every risk score used after kidney surgery. What it cannot do is tell you what will happen to you. Grade is one input among several, it is read alongside stage, tumour type and how completely the tumour was removed, and many people with a grade 3 tumour never see it return. Treat it as a reason for closer follow-up, not as a forecast.

Stage usually carries more weight. Stage describes where the cancer has actually reached: whether it is still inside the kidney, has grown into the surrounding fat or the renal vein, or has travelled to lymph nodes or other organs. That has the most direct bearing on what happens next. Grade describes only how the cells look. The two are not in competition, though. Grade adds information that stage alone misses, which is exactly why the risk scores used after surgery combine them. A high grade in a small, contained tumour is a very different situation from a high grade in disease that has already spread.

There is no single answer, and any page offering you one number is glossing over how this works. Grade 3 means the pathologist could see prominent nucleoli at low magnification: the cells are more abnormal than grade 1 or 2, and less so than grade 4. On its own that places the tumour in an intermediate to higher risk group, and it usually means closer surveillance after treatment. What it means for you depends far more on the stage, on whether the tumour was removed completely, on the tumour type and on your own health. Ask your oncologist to explain grade and stage together rather than reading the grade in isolation.

Fuhrman grading is still printed on many pathology reports in India and elsewhere, and the number on it still carries meaning, but it is no longer the current standard. The WHO/ISUP system replaced it because different pathologists applied the three combined features of the Fuhrman system inconsistently, which weakened it as a prognostic tool. WHO/ISUP grades 1 to 3 on a single feature and reserves grade 4 for markedly abnormal cells or for sarcomatoid and rhabdoid change. If your report says Fuhrman, it has not been graded wrongly. Read the number as the equivalent WHO/ISUP grade, and ask your oncologist to confirm how it was assigned.

Sarcomatoid or rhabdoid change means part of the tumour has lost its usual appearance and looks disorganised or spindle shaped. Any kidney cancer with these features is grade 4 by definition, whatever the rest of the slide shows, and as a group these tumours behave more aggressively and are followed much more closely. It is reported on its own line because it changes the discussion about systemic treatment, not just the number on the report. It is not a dead end, though. This is an area where modern immune based systemic therapy has changed what can be offered, and it is a conversation to have with a medical oncologist rather than a conclusion to draw from a report.

Grade itself cannot be changed, but what is done about it can. In practice a high grade mostly influences how intensively you are watched after treatment, meaning how often scans are done and for how long, along NCCN based follow-up schedules. Where the risk after surgery is judged to be high, adjuvant immunotherapy may be discussed. If disease is advanced, treatment is chosen from the immunotherapy, combination immunotherapy and targeted TKI classes. Systemic therapy, radiation and follow-up imaging are delivered in-house by our medical oncology team, while kidney surgery and ablation are coordinated with specialist urology, uro-oncology and interventional radiology partners.